Both [18F]TZ4877 (targeting S1PR1) and [18F]AV45 (targeting amyloid composition) showed increased uptake in the AD group; the increase of which can be reduced by EA treatment significantly only indicated by [18F]TZ4877 positron emission tomography (PET). This evidence concerns the gene S1PR1 and Alzheimer disease.